(Q37961280)

26 August 2017

Paediatric use of second-line anti-tuberculosis agents: a review (English)

1 reference

26 August 2017

0 references

James A Seddon

1

0 references

Helen McIlleron

object named as

Helen McIlleron

4

0 references

author name string

Anneke C Hesseling

2

1 reference

26 August 2017

Ben J Marais

3

1 reference

26 August 2017

Charles A Peloquin

5

1 reference

26 August 2017

Peter R Donald

6

1 reference

26 August 2017

H Simon Schaaf

7

1 reference

26 August 2017

25 November 2011

1 reference

26 August 2017

1 reference

26 August 2017

92

1 reference

26 August 2017

1

1 reference

26 August 2017

9-17

1 reference

Childhood tuberculosis: an emerging and previously neglected problem.

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Community-based therapy for children with multidrug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Multidrug-resistant tuberculous meningitis in children in Durban, South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Multidrug-resistant tuberculosis in children: two cases and a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Multidrug resistant tuberculosis in a 6 year old child.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Linezolid in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis in paediatric patients: Experience of a paediatric infectious diseases unit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Alcohol use as a risk factor for tuberculosis - a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Isoniazid pharmacokinetics in children treated for respiratory tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Clinical pharmacokinetics of the antituberculosis drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Low antituberculosis drug concentrations in patients with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Drug-resistant tuberculosis: pediatric guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Amikacin in the treatment of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Fluoroquinolones in paediatrics: a risk for the patient or for the community?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Pharmacokinetics of gatifloxacin in infants and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Levofloxacin pharmacokinetics in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

A multicentre study of the early bactericidal activity of anti-tuberculosis drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Fluoroquinolones, tuberculosis, and resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Crystal structure of the TetR/CamR family repressor Mycobacterium tuberculosis EthR implicated in ethionamide resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Population pharmacokinetics of ethionamide in patients with tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Cerebrospinal fluid concentrations of ethionamide in children with tuberculous meningitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Pharmacokinetics of ethionamide in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Pharmacokinetics of cycloserine and terizidone. A comparative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Once-daily and twice-daily dosing of p-aminosalicylic acid granules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Linezolid pharmacokinetics in pediatric patients: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Long-term linezolid treatment in a young child with extensively drug-resistant tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Serum concentrations and antituberculosis activity of thiacetazone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Susceptibility of multidrug-resistant strains of Mycobacterium tuberculosis to amoxycillin in combination with clavulanic acid and ethambutol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Antituberculosis activity of clarithromycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Pharmacokinetics of a clarithromycin suspension in infants and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

7 January 2021

Childhood tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Old and new drugs for the treatment of tuberculosis in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Drug-resistant tuberculosis: controversies and challenges in pediatrics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Sensorineural hearing loss in children after liver transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Aminoglycoside-induced ototoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Aminoglycoside induced ototoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Aminoglycoside-induced hearing loss in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

A rapid method for detection of five known mutations associated with aminoglycoside-induced deafness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

A molecular and cellular hypothesis for aminoglycoside-induced deafness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

A molecular basis for human hypersensitivity to aminoglycoside antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use--safety report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Quinolone arthropathy in animals versus children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Safety and efficacy of ciprofloxacin in paediatric patients--review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Fluoroquinolone antibiotics in infants and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Do fluoroquinolones commonly cause arthropathy in children?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Fluoroquinolones for treating tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Organic Iodine Inhibits Deoxyribonucleic Acid Synthesis and Growth in FRTL-5 Thyroid Cells*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Hypothyroidism due to ethionamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Ethionamide-induced goitrous hypothyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Abnormal thyroid function tests in children on ethionamide treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Reversible pellagra-like encephalopathy with ethionamide and cycloserine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Changes in serum transminase due to prothionamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

JAUNDICE DUE TO ETHIONAMIDE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Severe hypoglycaemia in the course of treatment with streptomycin, isoniazid and ethionamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Cycloserine in the treatment of pulmonary tuberculosis; a report on toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Treatment of drug-resistant cases of pulmonary tuberculosis with cycloserine and pyrazinamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Cycloserine-induced encephalopathy: evidence on brain MRI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Hypothyroidism in a patient receiving treatment for multidrug-resistant tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Para-aminosalicylic acid; a clinical trial in 10 patients with pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain. A report from the British Medical Research Council

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Immune thrombocytopenia due to a metabolite of para-aminosalicylic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Thrombocytopenia following administration of paraaminosalicylic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Thrombocytopenia induced by sodium para-aminosalicylic acid: report of a case

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Para-aminosalicylic acid-induced hypoglycaemia in a patient with diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Para-aminosalicylic acid-induced malabsorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Para-aminosalicylic acid as a cause of intestinal malabsorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Lymphoma-like syndrome following para-aminosalicylic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

International open trial of uniform multi-drug therapy regimen for 6 months for all types of leprosy patients: rationale, design and preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Update on the use of linezolid: a pediatric perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Use of linezolid in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Hematologic effects of linezolid in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Safety and tolerability of linezolid in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Linezolid for the treatment of multidrug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Linezolid in the treatment of multidrug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Multidrug-resistant tuberculosis and HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Chapter 19: Interactions between Antituberculosis and Antiretroviral Agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

Cloning and expression of Mycobacterium tuberculosis and Mycobacterium leprae dihydropteroate synthase in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2011.11.001

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TUBE.2011.11.001

1 reference

26 August 2017

1 reference